SCHEMBL268984

SCHEMBL268984

CCN(CC)CCN(C)Cc1cccc(C(=O)Nc2ccc(OCCCN3CCCCC3)cc2C(=O)NN=Cc2ccc(Cl)c(C(F)(F)F)c2)c1

nearest known ligand 0.53

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC34A2 O95436 11/20 0.53
POLB P06746 2/20 0.39
KDM4E B2RXH2 1/20 0.39
LMNA P02545 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
RAF1 P04049 1/20 0.38
MET P08581 3/20 0.37
BCHE P06276 1/20 0.37
ACHE P22303 1/20 0.37
HRH3 Q9Y5N1 1/20 0.36
MEN1 O00255 1/20 0.36
GAA P10253 1/20 0.36
MAPT P10636 1/20 0.36
HPGD P15428 1/20 0.36
HTT P42858 1/20 0.36
KMT2A Q03164 1/20 0.36
ASF1A Q9Y294 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL274483 1.00 SLC34A2 (0.53) SLC34A2POLBKDM4ELMNASMN1; SMN2
SCHEMBL268983 1.00 SLC34A2 (0.53) SLC34A2POLBKDM4ELMNASMN1; SMN2
SCHEMBL269171 0.90 SLC34A2 (0.55) SLC34A2
SCHEMBL269172 0.90 SLC34A2 (0.55) SLC34A2
SCHEMBL274879 0.90 SLC34A2 (0.55) SLC34A2
SCHEMBL274480 0.90 SLC34A2 (0.54) SLC34A2KDM4EMAPTHPGD
SCHEMBL269314 0.90 SLC34A2 (0.54) SLC34A2KDM4EMAPTHPGD
SCHEMBL269315 0.90 SLC34A2 (0.54) SLC34A2KDM4EMAPTHPGD
SCHEMBL267744 0.89 SLC34A2 (0.54) SLC34A2KDM4EMAPTHPGD
SCHEMBL267745 0.89 SLC34A2 (0.54) SLC34A2KDM4EMAPTHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 SLC34A2 6/4885POLB 3843/4885KDM4E 4468/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 SLC34A2 2/4885POLB 3761/4885KDM4E 4535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.